Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire, a global specialty biopharmaceutical company, has reported that its subsidiary Shire LLC has filed a lawsuit in the US District Court for the District of Delaware against Teva Pharmaceuticals USA, and Teva Pharmaceutical Industries, (collectively Teva) for the infringement of US Patent Nos 6,287,599 (’599 patent) and 6,811,794 (’794 patent).
Subscribe to our email newsletter
Shire said that the lawsuit results from an Abbreviated New Drug Application (ANDA) filed by Teva for generic versions of 1mg, 2mg, 3mg and 4mg guanfacine hydrochloride extended release tablets, Intuniv, which seeks to market such generic products before the expiration of the ’599 and ’794 patents.
Teva’s ANDA did not challenge, and the lawsuit does not currently assert the patent (US Patent No 5,854,290, Use of Guanfacine in the Treatment of Behavioral Disorders) which expires in 2015. The regulatory exclusivity period for Intuniv runs through September 2, 2012.
Intuniv is a once-daily, extended release formulation of guanfacine, designed to provide steady delivery of drug throughout the day. Intuniv is not a controlled substance and has no known potential for abuse or dependence.
Guanfacine, the active ingredient in Intuniv, is thought to work directly by binding selectively to alpha-2A adrenergic receptors located in the prefrontal cortex – an area of the brain that has been linked to ADHD.